The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
Open accessAbstract
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse Exon20ins were used to characterize the antitumor mechanism of amivantamab. Amivantamab inhibited proliferation by effectively downmodulating EGFR–MET levels and inducing immune-directed antitumor activity with increased IFNγ secretion in various models. Importantly, in vivo efficacy of amivantamab was superior to cetuximab or poziotinib, an experimental Exon20ins-targeted TKI. Amivantamab produced robust tumor responses in two Exon20ins patients, highlighting the important translational nature of this preclinical work. These findings provide mechanistic insight into the activity of amivantamab and support its continued clinical development in Exon20ins patients, an area of high unmet medical need. Significance: Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC. Preclinical data shown here, together with promising clinical activity in an ongoing phase I study, strongly support further clinical investigation of amivantamab in EGFR Exon20ins–driven NSCLC. This article is highlighted in the In This Issue feature, p. 1079
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These results were replicated in clinical trials (for example, NCT04538664), eventually leading to the approval of amivantamab by the EMA for the treatment of non-small cell lung cancer.”
From Human disease models in drug development (2023) · cites this paper as [115]
In the citing paper
“the efficacy of amivantamab, a bispecific antibody against EGFR and the mesenchymal–epithelial transition receptor, was preclinically tested in patient-derived cells and organoids that harbour EGFR Exon20ins mutations115.”
From Human disease models in drug development (2023) · cites this paper as [115]
Citations
Cites
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“Nearly 20% of Caucasians and up to 50% of Asians with lung adenocarcinomas harbor mutations in EGFR (3,4).”
BackgroundLong‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082 · cited 1×
“PDO Culture PDOs (YUO-029 and YUO-036) were established as described previously (46).”
MethodGazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991 · cited 1×
“tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and osimertinib (5,6).”
BackgroundRegulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891 · cited 1×
“It is known that inflammatory cytokines such as IFN-γ and TNFα are secreted from infected monocytes and activated NK cells during ADCC, encouraging antigen presentation and adaptive immune responses (36,37).”
BackgroundMutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775 · cited 1×
“Given that mutant TP53 is associated with EGFR-TKI resistance (30) and the depleted mutant TP53 restored the sensitivity of amivantamab by downregulation of p-ERK, induction of p-ERK following amivantamab treatment in YU-1163 cells might be a key regulator of cell survival potentially through the crosstalk between mut…”
BackgroundYasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · cited 1×
“In contrast, the EGFR exon 20 mutations encompass nucleotides that translate into amino acids at position 762-823, and include a C-helix (762–766) followed by a loop (767–775) (7).”
BackgroundNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567 · cited 1×
“The effector cells, mainly natural killer (NK) cells, trigger degranulation and subsequent cytokine production, resulting in the elimination of the target cells (33).”
BackgroundIntra-tumour diversification in colorectal cancer at the single-cell level
Roerink, S. F., Sasaki, N., Lee-Six, H., Young, M. D., Alexandrov, L. B., Behjati, S., Mitchell, T. J., Grossmann, S., Lightfoot, H., Egan, D. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0024-3 · Cited by 551
Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., Tenen, D. G., & Kobayashi, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040315 · Cited by 499 · cited 1×
“As EGFR-TKIs have been reported to drive apoptosis in NSCSL cells harboring sensitizing EGFR mutations (24,25), we investigated whether treatment with amivantamab resulted in engagement of the apoptotic machinery.”
Background
Cited by
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00662 · Cited by 655
“Median time from initial diagnosis, months (range) 37 (2-173) 17 (1-130)”
BackgroundSelf-citationThe past, present, and future of antibiotics
Cook, M. A., & Wright, G. D. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo7793 · Cited by 652
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403614 · Cited by 458
Self-citationEmerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
“expression and exhibited immune-directed antitumor activity, translating clinically into robust antitumor responses in two exon 20ins patients.(182) Notably, on May 21, 2021, the FDA granted accelerated approval to JNJ-61186372 (Rybrevant, Janssen Biotech, Inc.”
BackgroundPassaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Wang, J., Azuma, K., Juan-Vidal, O., Cobo, M., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.117 · Cited by 440
Self-citationFu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
“Amivantamab presented preclinical activity against EGFR-mutated NSCLC cells with EGFRTKIs resistance; importantly, the antitumor efficacy of amivantamab was also observed in two patients with exon20ins, which supports further clinical development [208, 209].”
BackgroundAmivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Zhou, C., Tang, K.-J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306441 · Cited by 381
Self-citationHuman disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
He, J., Huang, Z., Han, L., Gong, Y., & Xie, C. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5270 · Cited by 314
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Kaplon, H., & Reichert, J. M. (2021) · mAbs · doi:10.1080/19420862.2020.1860476 · Cited by 292
“Amivantamab has been shown to function through multiple mechanisms of action in preclinical models of NSCLC with EGFR exon 20 insertion driver mutations, which cause tumor cells to be insensitive to EGFR tyrosine kinase inhibitors.(98) FDA granted Breakthrough Therapy designation to amivantamab for the treatment of pa…”
BackgroundRiely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., Tsao, A. S., Patel, J. D., Gadgeel, S. M., Bazhenova, L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1598 · Cited by 222
“3), an intravenous bispecific antibody that targets EGFR and MET for patients with NSCLC with EGFRex20ins and other EGFR mutations (38, 39).”
BackgroundNagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219
Self-citationNew clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
“286 The ORR of avantumab reaches 40% in NSCLC with EGFR exon 20ins after platinum chemotherapy, and its potency in other tumors, such as gastroesophageal adenocarcinoma, is still being elucidated.”
BackgroundAizer, A. A., Lamba, N., Ahluwalia, M. S., Aldape, K., Boire, A., Brastianos, P. K., Brown, P. D., Camidge, D. R., Chiang, V. L., Davies, M. A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac118 · Cited by 202
“288 Of note, neratinib, a dual inhibitor of HER2 and EGFR, may have activity in select patients with EGFR mutations.”
BackgroundThe changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 182
“Amivantamab has demonstrated antitumour activity in NSCLC harbouring various EGFR mutations 54 , including EGFR exon20ins 55,56 , becoming an alternative treatment option for these patients.”
Dong, R.-F., Zhu, M.-L., Liu, M.-M., Xu, Y.-T., Yuan, L.-L., Bian, J., Xia, Y.-Z., & Kong, L.-Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105583 · Cited by 198
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Friedlaender, A., Subbiah, V., Russo, A., Banna, G. L., Malapelle, U., Rolfo, C., & Addeo, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00558-1 · Cited by 193
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190
“Preclinical and clinical data suggest that amivantamab, a bispecific antibody that targets EGFR and MET, may have efficacy for patients with NSCLC with EGFRex20ins mutations (50-52).”
BackgroundDiscovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
Neijssen, J., Cardoso, R. M. F., Chevalier, K. M., Wiegman, L., Valerius, T., Anderson, G. M., Moores, S. L., Schuurman, J., Parren, P. W. H. I., Strohl, W. R., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100641 · Cited by 167
“Based on its unique mode of action, which includes induction of trogocytosis from macrophages, ADCC from natural killer cells, and receptor–antibody complex internalization and lysosomal degradation (29, 42, 43), amivantamab may provide significant benefit to patients with NSCLC and other malignancies associated with…”
BackgroundAcquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 168
“Amivantamab (JNJ-61186372) is an EGFR/cMET targeted bispecific antibody.(36) A phase I study of 20 NSCLC patients with Ex20ins mutations demonstrated that the disease control rate of amivantamab is 100%, and the objective response rate (ORR) was 30%.”
BackgroundBispecific antibody drug conjugates: Making 1+1>2
Gu, Y., Wang, Z., & Wang, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.009 · Cited by 159
Kim, S.-Y., Kim, S.-M., Lim, S., Lee, J. Y., Choi, S.-J., Yang, S.-D., Yun, M. R., Kim, C. G., Gu, S. R., Park, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5026 · Cited by 151
“These data and our recent work on amivantamab, an EGFR-MET bispecific antibody for treatment of EGFR exon 20 insertions, underline the feasibility of PDO-based preclinical studies (50).”
BackgroundSelf-citationOverall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
Yang, J. C., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., Kim, Y. J., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503001 · Cited by 183
Self-citationOncogenic alterations in advanced NSCLC: a molecular super-highway
Friedlaender, A., Pérol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024) · Biomarker Research · doi:10.1186/s40364-024-00566-0 · Cited by 177
“One study compared it to poz-iotinib, another exon 20 insertion TKI being developed, and found far less skin toxicity with amivantamab [78].”
BackgroundSyed, Y. Y. (2021) · Drugs · doi:10.1007/s40265-021-01561-7 · Cited by 139
“Consistent with these findings, amivantamab decreased tumour volume in a patientderived xenograft mice model harbouring an EGFR Ex20ins mutation [12].”
BackgroundResultLeighl, N. B., Akamatsu, H., Lim, S. M., Cheng, Y., Minchom, A. R., Marmarelis, M. E., Sanborn, R. E., Yang, J. C., Liu, B., John, T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01001 · Cited by 139
Self-citationDevelopment of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 157
“Belantamab mafodotin is an ADC targeting BCMA that was developed for the treatment of relapsed or refractory multiple myeloma by GlaxoSmithKline [122] in the USA and European Union (EU) in August 2020, as a first-in-class drug [123].”
MethodEGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Remón, J., Hendriks, L. E. L., Cardona, A. F., & Besse, B. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102105 · Cited by 138
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Huang, S., van Duijnhoven, S. M. J., Sijts, A. J. A. M., & van Elsas, A. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03404-6 · Cited by 121
Cho, B. C., Kim, D., Spira, A. I., Gomez, J. E., Haura, E. B., Kim, S., Sanborn, R. E., Cho, E. K., Lee, K. H., Minchom, A. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02554-7 · Cited by 125
“…plus immunotherapy and anti-angiogenic therapy in this patient population 11 , but no subsequent targeted Article https://doi.org/10.1038/s41591-023-02554-7 downregulation of cell surface receptors and induce Fc-dependent tro-gocytosis and antibody-dependent cellular cytotoxicity 24–27 .”
BackgroundInfluentialSelf-citationFelip, E., Cho, B. C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A. I., Girard, N., Califano, R., Gadgeel, S. M., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.05.541 · Cited by 133
Self-citationReita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2021) · Cancers · doi:10.3390/cancers13194926 · Cited by 113
Meador, C. B., Sequist, L. V. D., & Piotrowska, Z. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0226 · Cited by 117
“This process is mediated by internalization and lysosomal degradation of the receptors, causing inhibition of downstream signaling and induction of apoptosis(41).”
Influential20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
Singh, S. K., Sadhukhan, S., & Sonawane, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188967 · Cited by 117
Araki, T., Kanda, S., Horinouchi, H., & Ohe, Y. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad052 · Cited by 116
“Specifically, it has antitumor activity against various activating and resistant EGFR mutations (del19, L858R, T790M, C797S and exon20 insertion) (81,82) and might have potential clinical use for osimertinib-resistant patients.”
BackgroundPrinciples and Current Clinical Landscape of Multispecific Antibodies against Cancer
Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 104
“Amivantamab‘s mode of action combines EGFR/MET downmodulation and NK/macrophage-dependent cancer-cell killing with minimal toxicity [83,84].”
BackgroundWu, L., Ke, L., Zhang, Z., Yu, J., & Meng, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602762 · Cited by 109
Cho, B. C., Felip, E., Hayashi, H., Thomas, M., Lu, S., Besse, B., Sun, T., Martinez, M., Sethi, S. N., Shreeve, S. M., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-0923 · Cited by 95
Self-citationSurowka, M., Schäfer, W. M., & Klein, C. (2021) · mAbs · doi:10.1080/19420862.2021.1967714 · Cited by 101
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
Zhou, Y., Penny, H. L., Kroenke, M. A., Bautista, B., Hainline, K. M., Chea, L. S., Parnes, J. R., & Mytych, D. T. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004225 · Cited by 97
Recent advances and challenges of bispecific antibodies in solid tumors
Wu, Y., Yi, M., Zhu, S., Wang, H., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00250-1 · Cited by 99
“In multiple preclinical models, potent in vivo antitumor efficacy of Amivantamab was observed [94].”
BackgroundCracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 114
The state of the art of bispecific antibodies for treating human malignancies
Wang, S., Chen, K., Lei, Q., Ma, P., Yuan, A. Q., Zhao, Y. J., Jiang, Y., Hong, F., Xing, S., Fang, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114291 · Cited by 86
Patient‐derived xenograft model in cancer: establishment and applications
Gu, A., Li, J., Li, M., & Liu, Y. (2025) · MedComm · doi:10.1002/mco2.70059 · Cited by 89
Antibody variable region engineering for improving cancer immunotherapy
Lou, H., & Cao, X. (2022) · 癌症:英文版 · doi:10.1002/cac2.12330 · Cited by 80
Hong, Y., Nam, S.-M., & Moon, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01433-6 · Cited by 80
Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 71
Pan, K., Concannon, K., Li, J., Zhang, J., Heymach, J. V., & Le, X. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00808-4 · Cited by 70
The future of tumor organoids in precision therapy
Kim, S., van de Wetering, M., Clevers, H. C., & Sanders, K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.03.005 · Cited by 68
Self-citationBauman, J. E., Saba, N. F., Roe, D. J., Bauman, J. R., Kaczmar, J. M., Bhatia, A. K., Muzaffar, J., Julian, R. A., Wang, S., Bearelly, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01994 · Cited by 58
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
Moosavi, F., Giovannetti, E., Peters, G. J., & Firuzi, O. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103234 · Cited by 62
Update on the Management of Brain Metastasis
Singh, K., Saxena, S., Khosla, A. A., McDermott, M. W., Kotecha, R. R., & Ahluwalia, M. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01312-w · Cited by 65
“1st, 2nd, and 3rd generation EGFR TKIs may prove helpful in uncommon EGFR mutations barring exon 20 insertions [70, 71].”
BackgroundYasuda, H., Ichihara, E., Sakakibara‐Konishi, J., Zenke, Y., Takeuchi, S., Morise, M., Hotta, K., Sato, M., Matsumoto, S., Tanimoto, A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.006 · Cited by 60
Bispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 57
Joosten, S. P. J., Spaargaren, M., Clevers, H. C., & Pals, S. T. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188437 · Cited by 49
Shen, P., Wang, Y., Jia, X., Xu, P., Qin, L., Feng, X., Li, Z., & Qiu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114551 · Cited by 45
Current status of immunotherapy for non-small cell lung cancer
Yang, T., Xiong, Y., Zeng, Y., Wang, Y., Zeng, J., Liu, J., Xu, S., & Li, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989461 · Cited by 49
“Amivantamab inhibits proliferation of tumor cell in NSCLC patients by effectively downregulating EGFR and MET gene levels and inducing immune antitumor activity and increasing IFNγ secretion (Yun et al., 2020).”
BackgroundSpira, A. I., Paz-Ares, L. G., Han, J., Shih, J., Mascaux, C., Roy, U. B., Zugazagoitia, J., Kim, Y. J., Chiu, C., Kim, S.-W., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.01.018 · Cited by 58
Self-citationThe promise of bispecific antibodies: Clinical applications and challenges
Lim, S. M., Pyo, K., Soo, R. A., & Cho, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102240 · Cited by 47
Self-citationResearch and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
Antonarelli, G., Giugliano, F., Corti, C., Repetto, M., Tarantino, P., & Curigliano, G. (2021) · Pharmaceuticals · doi:10.3390/ph14090884 · Cited by 49
“Amivantamab (JNJ-61186372) is a fully-human anti-EGFR/cMET bsAb with immune cell directing activity [33,41].”
BackgroundCancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
“Amivantamab, a bi-specific EGFR/MET antibody, has been recently approved for the treatment of NSCLC carrying insertions in exon 20 of the EGFR gene [18,19].”
BackgroundThe application of patient-derived organoid in the research of lung cancer
Li, Y., Gao, X., Ni, C., Zhao, B. T., & Cheng, X. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00771-3 · Cited by 45
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Gou, Q., Gou, Q., Gan, X., & Xie, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-61087-2 · Cited by 49
Cho, B. C., Li, W., Spira, A. I., Sauder, M. B., Feldman, J., Bozorgmehr, F., Mak, M. P., Smith, J., Voon, P. J., Liu, B., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.07.117 · Cited by 40
Self-citationYao, H., Tong, X., Hudson, R., & Wang, M. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01711-x · Cited by 38
Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 41
Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review
Khosla, A. A., Jatwani, K., Singh, R., Reddy, A., Jaiyesimi, I. A., & Desai, A. P. (2023) · Pharmaceuticals · doi:10.3390/ph16101461 · Cited by 46
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors
Gu, Y., & Zhao, Q. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00734-w · Cited by 43
“A preclinical study demonstrated that amivantamab showed significant antitumor activity against EGFR Exon 20 insertion mutations in NSCLC across various models [68].”
BackgroundBrazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 40
Therapeutic antibodies for the prevention and treatment of cancer
Kumar, M., Jalota, A., Sahu, S. K., & Haque, S. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00996-w · Cited by 39
“Simultaneous blocking of the two pathways by the bispecific antibody shows increased selectivity and synergistic effect which can be explained by avidity effect [53].”
BackgroundThe immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
Kirchner, M., Kluck, K., Brandt, R., Volckmar, A., Penzel, R., Kazdal, D. N., Endris, V., Neumann, O., Seker‐Cin, H., Goldschmid, H., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100253 · Cited by 45
“60,61 To date, no targeted therapies are approved for patients with NSCLC with EGFR or ERBB2 exon 20-activating mutations, which presents an unmet clinical need.”
Minchom, A. R., Viteri, S., Bazhenova, L. A., Gadgeel, S. M., Ou, S. I., Trigo, J. M., Bauml, J. M., Backenroth, D., Bhattacharya, A., Li, T. M. W. Y., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.005 · Cited by 39
Besse, B., Goto, K., Wang, Y., Lee, S., Marmarelis, M. E., Ohe, Y., Bernabé, R., Kim, D., Lee, J.-S., Cousin, S., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.029 · Cited by 60
Self-citationBispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Guidi, L., Etessami, J. D., Valenza, C., Valdivia, A., Meric‐Bernstam, F., Felip, E., & Curigliano, G. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473148 · Cited by 44
Immunotherapeutic progress and application of bispecific antibody in cancer
Kang, J., Sun, T., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020003 · Cited by 42
“Amivantamab binds to the extracellular domains of EGFR and cMet and blocks the binding of the ligand EGF to EGFR and the binding of the ligand HGF to its receptor cMet; it also induces degradation of both receptors in vivo, extending its effects to Ligand-independent receptor-driven diseases are included (99), and can…”
BackgroundSentana‐Lledo, D., Academia, E. C., Viray, H., Rangachari, D., Kobayashi, S. S., VanderLaan, P. A., & Costa, D. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-98 · Cited by 40
“Amivantamab is a humanized, bispecific antibody that binds EGFR and MET extracellularly to target activating mutations, including EGFR exon 20 insertion mutations, as well as MET mutations and amplification (89).”
Zhang, Y., Wu, Z., Yang, Y., Wang, J., Li, J., Sun, Z., Teng, Q., Ashby, C. R., & Yang, D. (2020) · Cancers · doi:10.3390/cancers12113249 · Cited by 32
“Given that poziotinib is an EGFR inhibitor [71], we evaluated the effect of poziotinib on the expression level of the Akt protein.”
BackgroundBoch, T., Köhler, J., Janning, M., & Loges, S. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0540 · Cited by 35
Emerging paradigms and recent progress in targeting ErbB in cancers
Stoup, N., Liberelle, M., Lebègue, N., & SEUNINGEN, I. V. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.009 · Cited by 33
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Vyse, S., & Huang, P. H. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2016397 · Cited by 38
“There is currently no evidence to suggest EGFR kinase domain mutations alter the extracellular EGFR domain and indeed, amivantamab does not demonstrate good mutant over WT selectivity for EGFR exon 20 insertion mutations in vitro [78].”
BackgroundInfluentialPark, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A. I., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.008 · Cited by 31
Self-citation[Pharmacokinetics and metabolism of trazodone in man (author's transl)].
Jauch, R., Kopitar, Z., Prox, A., & Zimmer, A. (1976) · PubMed · Cited by 50
Cho, B. C., Loong, H. H.-F., Tsai, C., Teo, M. L., Kim, H. R., Lim, S. M., Jain, S., Olsen, S., & Park, K. (2022) · Current Oncology · doi:10.3390/curroncol29030174 · Cited by 33
“Effective treatment has been established for many uncommon EGFR-activating mutations [29], and there has been much effort to develop medicines that target EGFR exon 20 insertions [30,31] and C797X mutations [32].”
BackgroundSelf-citationTargeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
Seo, D., & Lim, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115917 · Cited by 34
“Amivan-tamab significantly reduces the viability of cell lines (Ba/F3) and patient-derived organoids harboring EGFR exon 20 insertions [38].”
BackgroundOptimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 34
“Approved by the FDA for patients with EGFR exon 20 insertions [295], amivantamab also offers activity in tumors partially responsive to osimer-tinib [296].”
Lopatnikova, J., & Sennikov, S. V. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679092 · Cited by 31
Huang, W., Li, F., Gong, Y., Zhang, Y., Youngsaye, W., Xu, Y., Zhu, X., Greenfield, M. T., Kohlmann, A., Taslimi, P. M., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129084 · Cited by 33
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Wang, K., Du, R. R., Myall, N. J., Lewis, W. E., Uy, N. F., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A. S., Cascone, T., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.020 · Cited by 32
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
Liguori, L., Polcaro, G., Nigro, A., Conti, V., Sellitto, C., Perri, F., Ottaiano, A., Cascella, M., Zeppa, P., Caputo, A., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112442 · Cited by 30
“In Non-Small Cell Lung Cancer (NSCLC), MET amplification drives EGFR-inhibitor resistance by activating EGFRindependent phosphorylation of ErbB3 and downstream activation of the PI3K/AKT pathway.”
BackgroundInfluentialTaverna, J. A., Hung, C., Williams, M. H., Williams, R., Chen, M., Kamali, S., Sambandam, V., Chiu, C. H.-L., Osmulski, P. A., Gaczynska, M. E., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2024.107533 · Cited by 36
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 34
“Amivantamab has also shown superior efficacy to poziotinib in tackling EGFR Ex20ins NSCLC with lower skin toxicity and loss of body weight in mice.(31) Promising clinical activity has been observed in the phase 1 first-in-human study CHRYSALIS (NCT02609776) involving 50 NSCLC patients with 13 distinct EGFR Ex20ins mut…”
BackgroundCHOUAID, C., Filleron, T., Debieuvre, D., Pérol, M., Girard, N., Dansin, É., Léna, H., Gervais, R., Cousin, S., Otto, J., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00848-9 · Cited by 26
Systemic Therapy for Lung Cancer Brain Metastases
Pellerino, A., Bruno, F., Rudà, R., & Soffietti, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00911-7 · Cited by 27
Chen, J., & Na, F. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1066869 · Cited by 27
“As observed in the organoid model, amivantamab has potent antitumor activity in NSCLC patients with EGFR exon20ins disease (Yun et al., 2020; Park et al., 2021).”
BackgroundAdvances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
Low, J. L., Lim, S. M., Lee, J. B., Cho, B. C., & Soo, R. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146131 · Cited by 28
Self-citationGuo, X., Wu, Y., Ying, X., Xie, N., & Shen, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291836 · Cited by 29
Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 26
“Its antitumor activity functions by disrupting EGFR and MET signaling functions by blocking ligand binding, producing lysosomal degradation of EGFR and MET receptors, and inducing Fc-mediated antibodydependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) [90,91].”
BackgroundInfluential
Metadata
- Authors
- Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., Lim, S. M., Hong, M. H., Kim, H. R., Thayu, M., Curtin, J. C., Knoblauch, R. E., Lorenzi, M. V., Roshak, A., & Cho, B. C.
- Affiliations
- Yonsei University (KR)
- Jeuk (South Korea) (KR)
- 4Janssen Research and Development, Spring House, Pennsylvania.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1194-1209
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3024670790
- Cited by
- 297
- References
- 47
- Citations by year
- 2026: 32 · 2025: 60 · 2024: 45 · 2023: 52 · 2022: 49 · 2021: 47 · 2020: 11
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Ministry of Science, ICT and Future Planning (NRF-2016R1A2B3016282, 2018R1C1B6008916)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- amivantamab, EGFR-MET bispecific antibody, EGFR exon 20 insertion, non-small cell lung cancer, anticancer activity, EGFR tyrosine kinase inhibitors, immune checkpoint blockade, interferon-gamma, patient-derived organoids, xenograft models, cetuximab, poziotinib, Ba/F3 cells
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Carcinoma, Non-Small-Cell Lung, Exons, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mutation, Antibodies, Bispecific, Proto-Oncogene Proteins c-met, Cell Line, Tumor, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.